Literature DB >> 3015851

Liposoluble platinum(II) complexes with antitumor activity.

M Maeda, N A Uchida, T Sasaki.   

Abstract

Seventeen liposoluble bis(carboxylato)-cyclohexane-1,2-diammineplatinum(II) and bis(carboxylato)-cis-diammineplatinum(II) complexes were synthesized and tested for antitumor activity against leukemia L1210 cells in mice. The former complexes had excellent antitumor activity without any toxicity to the host at the therapeutic dose when used with lipiodol as a carrier solvent. The latter complexes had neither antitumor activity nor toxicity in vivo. The former complexes were gradually released from lipiodol to saline in vitro; the latter were not. The activity depended on the chain length of the carboxylato residue and also on the molecular shape of the ligand part of the complexes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3015851

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  20 in total

1.  Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma.

Authors:  Yukinori Imai; Taku Chikayama; Manabu Nakazawa; Kazuhiro Watanabe; Satsuki Ando; Yoshie Mizuno; Kiyoko Yoshino; Kayoko Sugawara; Kazuhiro Hamaoka; Kenji Fujimori; Mie Inao; Nobuaki Nakayama; Masashi Oka; Sumiko Nagoshi; Satoshi Mochida
Journal:  J Gastroenterol       Date:  2011-10-06       Impact factor: 7.527

2.  Transarterial chemoembolization with miriplatin-lipiodol emulsion for neuroendocrine metastases of the liver.

Authors:  Jin Iwazawa; Shoichi Ohue; Keigo Yasumasa; Takashi Mitani
Journal:  World J Radiol       Date:  2010-12-28

3.  Antitumor effect of miriplatin-lipiodol suspension/emulsion using a VX2 liver tumor model.

Authors:  Yuki Tomozawa; Norihisa Nitta; Shinji Ohta; Hideji Otani; Shobu Watanabe; Akinaga Sonoda; Keiko Tsuchiya; Ayumi Nitta-Seko; Masashi Takahashi; Kiyoshi Murata
Journal:  Jpn J Radiol       Date:  2013-07-05       Impact factor: 2.374

Review 4.  Advances in platinum cancer chemotherapy. Advances in the design of cisplatin analogues.

Authors:  P C Hydes; M J Russell
Journal:  Cancer Metastasis Rev       Date:  1988-04       Impact factor: 9.264

5.  A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma.

Authors:  Takuji Okusaka; Hiroshi Kasugai; Hiroshi Ishii; Masatoshi Kudo; Michio Sata; Katsuaki Tanaka; Yasukazu Shioyama; Kazuaki Chayama; Hiromitsu Kumada; Masaharu Yoshikawa; Toshihito Seki; Hidetugu Saito; Naoaki Hayashi; Keiko Shiratori; Kiwamu Okita; Isao Sakaida; Masao Honda; Yukio Kusumoto; Takuya Tsutsumi; Kenji Sakata
Journal:  Invest New Drugs       Date:  2011-12-21       Impact factor: 3.850

6.  A case of advanced hepatocellular carcinoma with portal vein tumor thrombus refractory to epirubicin that showed marked decrease in tumor markers after transcatheter arterial infusion with miriplatin.

Authors:  Hiroki Nishikawa; Tadashi Inuzuka; Haruhiko Takeda; Jun Nakajima; Azusa Sakamoto; Sinichiro Henmi; Tetsurou Ishikawa; Sumio Saito; Ryuichi Kita; Toru Kimura; Yukio Osaki; Yorimitsu Koshikawa
Journal:  Case Rep Oncol       Date:  2010-06-30

7.  Local tumor progression following lipiodol-based targeted chemoembolization of hepatocellular carcinoma: a retrospective comparison of miriplatin and epirubicin.

Authors:  Jin Iwazawa; Shoichi Ohue; Naoko Hashimoto; Takashi Mitani
Journal:  Cancer Manag Res       Date:  2012-04-19       Impact factor: 3.989

8.  Transcatheter arterial chemotherapy with miriplatin for hepatocellular carcinoma patients with chronic renal failure: report of three cases.

Authors:  Norihiro Imai; Kenji Ikeda; Yuya Seko; Yusuke Kawamura; Hitomi Sezaki; Tetsuya Hosaka; Norio Akuta; Masahiro Kobayashi; Satoshi Saitoh; Fumitaka Suzuki; Yoshiyuki Suzuki; Yasuji Arase; Hiromitsu Kumada
Journal:  Gut Liver       Date:  2013-03-14       Impact factor: 4.519

9.  Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma.

Authors:  Takuji Okusaka; Shuichi Okada; Toshio Nakanishi; Shigetoshi Fujiyama; Yasuhiko Kubo
Journal:  Invest New Drugs       Date:  2004-04       Impact factor: 3.651

10.  Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis.

Authors:  Mitsuharu Hanada; Akemi Baba; Yasuyuki Tsutsumishita; Toshihiro Noguchi; Takashi Yamaoka; Nobuyoshi Chiba; Fumio Nishikaku
Journal:  Cancer Chemother Pharmacol       Date:  2008-12-24       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.